Alpa Laboratories Ltd

Alpa Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a risky to an attractive valuation grade. This change, coupled with its current price-to-earnings (P/E) ratio of 9.85 and price-to-book value (P/BV) of 0.79, positions the stock as a potentially undervalued opportunity relative to its historical averages and peer group.

Alpa Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Alpa Laboratories Ltd., a micro-cap pharmaceutical manufacturer with a market capitalisation of ₹148.00 crores, reported a net profit of ₹1.38 crores for Q4 FY26, marking a sharp recovery from the previous year's loss of ₹2.12 crores. However, the positive earnings reversal conceals troubling revenue trends, as net sales declined 21.34% year-on-year to ₹31.40 crores, raising questions about the sustainability of the company's business momentum in an otherwise buoyant pharmaceutical sector.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 May 2026, providing investors with the latest perspective on the company’s position.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 09 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Alpa Laboratories Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

At Rs 62.10, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Alpa Laboratories Ltd locked at its upper circuit of 20% on 6 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alpa Laboratories Ltd’s share price declined sharply to hit a new 52-week low of Rs.49.05 on 30 March 2026, marking a significant downturn amid broader market weakness and company-specific performance concerns. The stock’s recent slide reflects a continuation of negative trends in both financial results and technical indicators.

For the fifth consecutive session, Alpa Laboratories Ltd closed lower, hitting a fresh 52-week low of Rs 54.1 on 27 Mar 2026. This marks a steep 54.5% decline from its 52-week high of Rs 118.8, underscoring sustained selling pressure amid a challenging market backdrop.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Despite a broader market rally, Alpa Laboratories Ltd has plunged to its lowest price in 52 weeks, closing near Rs 54.56 on 23 Mar 2026. This decline comes amid a backdrop of weakening financial performance and persistent selling pressure that has pushed the stock down by nearly 49% over the past year.

Alpa Laboratories Ltd has reached a new 52-week low, reflecting a sustained decline in its share price amid broader market gains. The stock’s recent performance highlights ongoing concerns within the Pharmaceuticals & Biotechnology sector, with the share price now trading below all key moving averages.

Alpa Laboratories Ltd has touched a new 52-week low of Rs.54.56 today, marking a significant decline in its stock price amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and market sentiment.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 13 March 2026, providing investors with the latest insights into its performance and prospects.

Alpa Laboratories Ltd has reached a new 52-week low, reflecting ongoing pressures in its share price as it closed at Rs 62.85, marking a significant decline from its peak of Rs 120.5 over the past year. This development underscores the challenges faced by the company within the Pharmaceuticals & Biotechnology sector amid a broader market downturn.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing challenges reflected in its financial and market performance.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing underperformance relative to broader market indices and sector peers.